Page 3 - Max Colao News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Max colao. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Max Colao Today - Breaking & Trending Today

Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights


Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights
Over 250 patient start forms received by the end of the first quarter – – Cash and cash equivalents, and investments of $360.9 million at March 31, 2021 – – Conference call to be hosted today at 5:00 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars. “2021 started with the FDA …
– Over 250 patient start forms received by the end of the first quarter –
– Cash and cash equivalents, and investments of $360.9 million at March 31, 2021

– Conference call to be hosted today at 5:00 p.m. ET – ....

United States , United Kingdom , Max Colao , Peter Greenleaf , Glenn Schulman , Dana Lynch , European Congress , Nephrology Virtual Congress , Contract Research Organization , Aurinia Pharmaceuticals Inc , Exchange Commission Electronic Document Gathering , Aurinia Alliance , Corporate Communications , European Medicines Agency , Aurinia Pharmaceuticals , Company Quarterly Report On Form , Patient Marketing Campaign , Chief Executive Officer , Commercial Launch , Marketing Campaign , Chief Commercial Officer , Annual European Congress , Quarter Ended March , Quarterly Report , British Columbia , Annual Report ,

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights (Reports Cash Liquidity of US $423M)


- Cash, cash equivalents, and investments of $423 million at December 31, 2020 -
Victoria, BC, March 3, 2021 (T-Net)
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) today issued its financial results for the fourth quarter and year ended December 31, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars.
Over the past year, Aurinia matured into a fully-integrated biopharmaceutical company with capabilities spanning R&D, clinical, regulatory, CMC, and commercial. The recent FDA approval and immediate launch of LUPKYNIS underscores the exemplary performance and expertise of the Aurinia team,
commented Peter Greenleaf, President and Chief Executive Officer of Aurinia.
During 2020, we made calculated investments following the positive AURORA clinical trial results by building out a world-class commercial team, signing a major ex-US partnership with Otsuka, and ensuring we can meet future market demand for LUPKYNIS by securing our su ....

United States , United Kingdom , Switzerland General , Max Colao , Peter Greenleaf , Contract Research Organization , Aurinia Pharmaceuticals Inc , Company Annual Report On Form , Lonza Ltd , European Union , Aurinia Pharmaceuticals , Otsuka Pharmaceutical Co Ltd , Chief Executive Officer , Chief Commercial Officer , Commercial Launch , Priority Review , Fast Track , Licensing Agreement , Year Ended December , Fourth Quarter Ended December , Annual Report , British Columbia , Common Shares , ஒன்றுபட்டது மாநிலங்களில் , ஒன்றுபட்டது கிஂக்டம் , சுவிட்சர்லாந்து ஜநரல் ,

Aurinia Pharmaceuticals Inc (AUPH) Q4 2020 Earnings Call Transcript


Operator
Greetings, and welcome to the Aurinia Year-end 2020 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is recorded. It s now my pleasure to turn the call over to Glenn Schulman, Senior Vice President, Investor Relations. Please go ahead, sir.
Glenn Schulman
Senior Vice President, Corporate Communications and Investor Relations
Thank you, Kevin, and good afternoon, everyone. I m pleased to welcome you to today s call discussing Aurinia s fourth quarter and year-end financial results. Joining me on the call this afternoon are Peter Greenleaf, President and CEO of Aurinia; Neil Solomons, our Chief Medical Officer; Max Colao, Chief Commercial Officer; and Joe Miller, our Chief Financial Officer. This afternoon, just after 4:00 p.m., we issued a press release announcing our financial results and recent operational highlights, which is accessible from our website at www.auriniapharma.com and has been filed on a Form 8-K ....

United States , Switzerland General , Peter Greenleaf , Glenn Schulman , Maury Raycroft , Neil Solomons , Max Colao , Alethia Young , Justin Kim , Emily Cantor Fitzgerald , Joe Miller , Otsuka Pharmaceuticals , Aurinia Pharmaceuticals Inc , Aurinia Alliance , Maurice Thomas Raycroft Jefferies , Exchange Commission , Cowen Company , Justin Alexander Kim Oppenheimer Co , Cantor Fitzgerald , Corporate Communications , Devices Agency , Company Analyst , Aurinia Year End , Results Conference , Senior Vice President , Vice President ,

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights


Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death – – Cash, cash equivalents, and investments of $423 million at December 31, 2020 – – Conference call to be hosted today at 4:30 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the fourth quarter …

LUPKYNIS
TM is the first FDA-approved oral therapy for lupus nephritis (LN), a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death – ....

United States , United Kingdom , Switzerland General , Max Colao , Peter Greenleaf , Glenn Schulman , Dana Lynch , Contract Research Organization , Aurinia Pharmaceuticals Inc , Exchange Commission Electronic Document Gathering , Company Annual Report On Form , Lonza Ltd , Corporate Communications , European Union , Aurinia Pharmaceuticals , Otsuka Pharmaceutical Co Ltd , Chief Executive Officer , Chief Commercial Officer , Commercial Launch , Priority Review , Fast Track , Licensing Agreement , Year Ended December , Fourth Quarter Ended December , Annual Report , British Columbia ,